Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - ganirelix, quantity: 0.25 mg - injection, solution - excipient ingredients: glacial acetic acid; water for injections; mannitol; sodium hydroxide - for the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 30 mg (equivalent: risedronic acid, qty 27.84 mg) - tablet, film coated - excipient ingredients: crospovidone; hypromellose; macrogol 400; hyprolose; titanium dioxide; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; macrogol 8000; lactose monohydrate - treatment of paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 5 mg (equivalent: risedronic acid, qty 4.64 mg) - tablet, film coated - excipient ingredients: iron oxide yellow; microcrystalline cellulose; titanium dioxide; hypromellose; crospovidone; hyprolose; colloidal anhydrous silica; macrogol 8000; macrogol 400; lactose monohydrate; magnesium stearate - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - estradiol hemihydrate, quantity: 1 mg; progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: mono- and di- glycerides; gelatin; glycerol; purified water; lauroyl macrogolglycerides; hydrolysed gelatin; allura red ac; titanium dioxide; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400 - bijuva 1/100 is indicated for use during continuous combined hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: lactose; hypromellose; microcrystalline cellulose; magnesium stearate; polysorbate 80; titanium dioxide; macrogol 400; allura red ac aluminium lake; brilliant blue fcf aluminium lake - seasonique is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - oxybutynin, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: triacetin; ethyl acetate; povidone; 2-ethylhexyl acrylate; hexamethylene glycol dimethacrylate; cyclohexane; dilauroyl peroxide; isopropyl alcohol; dimeticonol; methicone; dibutyltin diacetate; heptane; toluene; aminoethylaminopropyl trimethoxysilane; polyethylene terephthalate; ethylene/vinyl acetate copolymer - oxytrol is indicated for the treatment of overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 150 mg - tablet, film coated - excipient ingredients: macrogol 8000; microcrystalline cellulose; hyprolose; colloidal anhydrous silica; hypromellose; crospovidone; indigo carmine; titanium dioxide; magnesium stearate; macrogol 400 - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium, quantity: 35 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; stearic acid; purified talc; microcrystalline cellulose; triethyl citrate; iron oxide yellow; magnesium stearate; disodium edetate; methacrylic acid - ethyl acrylate copolymer (1:1); sodium starch glycollate type a; simethicone; colloidal anhydrous silica - treatment of osteoporosis. treatment of glucocorticoid-induced osteoporosis. preservation of bone mineral density in patients on long term corticosteroid therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; benzalkonium chloride; benzyl alcohol; mannitol; methionine; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.